Revenue growth remains highly volatile, fluctuating between a 19.2% contraction and a 164.3% expansion, while gross margins exhibit instability, swinging from -22.9% in 2025Q3 to 60.2% in 2025Q4.
| Sales/Revenue | 1M | 1.01M | 607.57K | 253.57K | 223.21K | 1.16M | 2.18M |
| Revenue Growth % | 46.52% | 65.49% | 139.61% | 13.6% | -80.76% | -46.81% | - |
| Cost of Goods Sold | 794.14K | 781.7K | 384.76K | 474.55K | 432.37K | 850.74K | 702.99K |
| COGS % of Revenue | - | 77.74% | 63.33% | 187.15% | 193.71% | 73.32% | 32.23% |
| Gross Profit | 209.87K | 223.78K | 222.81K | -220.98K | -209.16K | 309.6K | 1.48M |
| Gross Margin % | 20.9% | 22.26% | 36.67% | -87.15% | -93.71% | 26.68% | 67.77% |
| Gross Profit Growth % | - | 0.43% | 200.83% | -5.65% | -167.56% | -79.06% | - |
| Operating Expenses | 8.15M | 7.98M | 9.94M | 4.93M | 1.54M | 1.43M | 1.9M |
| OpEx % of Revenue | - | 793.89% | 1635.64% | 1945.64% | 690.51% | 123.56% | 86.94% |
| Selling, General & Admin | 6.48M | 6.28M | 5.02M | 4.24M | 1.3M | 1.12M | 1.46M |
| SG&A % of Revenue | - | 624.57% | 827.06% | 1672.83% | 584.08% | 96.12% | 66.84% |
| Research & Development | 1.98M | 2.11M | 4.99M | 691.77K | 525.56K | 5.51M | 806.68K |
| R&D % of Revenue | - | 209.47% | 820.73% | 272.81% | 235.46% | 474.94% | 36.98% |
| Other Operating Expenses | -310.89K | -403.62K | -73.77K | 0 | -288K | -5.19M | -368.11K |
| Operating Income | -7.94M | -7.76M | -9.71M | -5.15M | -1.75M | -1.12M | -418.13K |
| Operating Margin % | -791.09% | -771.64% | -1598.97% | -2032.78% | -784.22% | -96.88% | -19.17% |
| Operating Income Growth % | - | 20.14% | -88.47% | -194.47% | -55.72% | -168.84% | - |
| EBITDA | -7.85M | -7.68M | -9.65M | -5.05M | -1.67M | -1.05M | -390.26K |
| EBITDA Margin % | -781.94% | -763.39% | -1588.48% | -1993.2% | -748.92% | -90.69% | -17.89% |
| EBITDA Growth % | 23.3% | 20.47% | -90.95% | -202.35% | -58.86% | -169.64% | - |
| D&A (Non-Cash Add-back) | 91.94K | 82.87K | 63.74K | 100.37K | 78.79K | 71.78K | 27.86K |
| EBIT | -7.58M | -7.36M | -7.95M | -1.53M | -2.19M | -1.09M | -369.04K |
| Net Interest Income | -7.4K | -7.8K | -7.91K | -2.29M | -3.99M | -3.17M | -2.68M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 7.4K | 7.8K | 7.91K | 2.29M | 3.99M | 3.17M | 2.68M |
| Other Income/Expense | 361.42K | 390.25K | 1.76M | 1.34M | -4.43M | -3.14M | -2.63M |
| Pretax Income | -7.58M | -7.37M | -7.96M | -3.81M | -6.18M | -4.26M | -3.05M |
| Pretax Margin % | -755.1% | -732.82% | -1309.37% | -1503.93% | -2767.5% | -367.07% | -139.71% |
| Income Tax | -63 | 0 | 250 | 250 | 500 | 1K | 1K |
| Effective Tax Rate % | 0% | 0% | -0% | -0.01% | -0.01% | -0.02% | -0.03% |
| Net Income | -7.58M | -7.37M | -7.95M | -3.77M | -6.18M | -4.25M | -3.03M |
| Net Margin % | -755.16% | -732.82% | -1308.01% | -1485.06% | -2769.49% | -366.42% | -139.08% |
| Net Income Growth % | 26.09% | 7.28% | -111.04% | 39.08% | -45.39% | -40.15% | - |
| Net Income (Continuing) | -7.58M | -7.37M | -7.96M | -3.81M | -6.18M | -4.26M | -3.05M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -84.7K | -83.76K | -80.59K | -72.04K | -572.32K | -576.26K | -569.29K |
| EPS (Diluted) | -4.39 | -11.73 | -74.20 | -3.80 | -4.28 | -2.96 | -2.08 |
| EPS Growth % | 77.04% | 84.19% | -1852.63% | 11.21% | -44.59% | -42.31% | - |
| EPS (Basic) | - | -11.73 | -74.20 | -3.80 | -4.28 | -2.96 | -2.08 |
| Diluted Shares Outstanding | 1.73M | 670.21K | 113.65K | 990.07K | 1.45M | 1.45M | 1.45M |
| Basic Shares Outstanding | 1.73M | 670.21K | 113.65K | 990.07K | 1.45M | 1.45M | 1.45M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Imminent Liquidity Exhaustion
As reported in recent financial filings, 60 Degrees Pharmaceuticals exhibits highly inconsistent quarterly revenue growth, with figures fluctuating between a 19.2% contraction and a 164.3% expansion, suggesting that the commercial adoption of Arakoda remains sensitive to seasonal demand and lacks a predictable, scalable trajectory.
The erratic nature of top-line performance indicates that the company has yet to establish a reliable recurring revenue base. Investors should monitor whether future periods demonstrate stabilization, as current growth appears driven by sporadic procurement rather than consistent market penetration.
Based on the company's reported income statements, gross margins have demonstrated extreme volatility, swinging from a negative 22.9% in 2025Q3 to a peak of 60.2% in 2025Q4, which highlights significant challenges in managing unit production costs and potential inventory-related accounting adjustments.
This lack of margin consistency suggests that the firm lacks the pricing power or operational scale necessary to absorb manufacturing fluctuations. The inability to maintain a stable gross margin profile complicates long-term profitability projections and warrants further investigation into the underlying cost of goods sold.
According to the provided income statement data, SXTP's operating expenses consistently dwarf gross profit, resulting in deep operating losses that reached as high as $4.2 million in 2024Q2, indicating a failure to achieve meaningful operating leverage despite the commercial launch of its primary product.
The persistent gap between revenue generation and overhead suggests that the current business model is heavily reliant on external funding to sustain operations. Without a substantial increase in prescription volume, the company appears unlikely to achieve the operating efficiency required to reach break-even status.
Financial statements reveal that the company's cash burn rate significantly exceeds its revenue generation, with operating losses frequently exceeding $2 million per quarter, which suggests that the current commercial strategy may be unsustainable without immediate and potentially dilutive capital market intervention.
Short-term observers may focus on the company's inability to convert its niche regulatory approval into a self-sustaining financial engine. The reliance on equity financing to cover ongoing R&D and SG&A costs poses a material risk to existing shareholders, as the path to positive cash flow remains obscured.
Quick answers to the most common questions about buying SXTP stock.
For fiscal year 2025, 60 Degrees Pharmaceuticals, Inc. (SXTP) reported total revenue of $1.0M. This represents a 53.9% decline compared to $2.2M in 2020.
60 Degrees Pharmaceuticals, Inc. (SXTP) reported a net loss of $7.4M for the fiscal year ending 2025.
60 Degrees Pharmaceuticals, Inc. (SXTP) reported an operating income of $-7.8M, resulting in an operating profit margin of -771.6%. This margin reflects the operational efficiency of the business before interest and taxes.
60 Degrees Pharmaceuticals, Inc. (SXTP) generated $0.2M in gross profit for the year, representing a gross profit margin of 22.3%. This demonstrates the company's core pricing power and production efficiency.